Patents by Inventor Ronald John Roberts

Ronald John Roberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydrogen sulfate salt
    Patent number: 9562017
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: February 7, 2017
    Assignees: AsrtaZeneca AB, Array BioPharma Inc.
    Inventors: John DeMattei, Tsung-Hsun Chuang, Gorkhn Sharma-Singh, Paul Alfred Dickinson, Mohammed Pervez, Richard Anthony Storey, Christopher John Squire, James Gair Ford, Ronald John Roberts
  • Novel Hydrogen Sulfate Salt
    Publication number: 20160024018
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Application
    Filed: April 28, 2015
    Publication date: January 28, 2016
    Inventors: John DeMattei, Tsung-Hsun Chuang, Gorkhn Sharma-Singh, Paul Alfred Dickinson, Mohammed Pervez, Richard Anthony Storey, Christopher John Squire, James Gair Ford, Ronald John Roberts
  • Hydrogen sulfate salt
    Patent number: 9156795
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: October 13, 2015
    Assignees: Array BioPharma, Inc., Astrazeneca AB
    Inventors: John DeMattei, Tsung-Hsun Chuang, Christopher John Squire, Ronald John Roberts, Gorkhn Sharma-Singh, Mohammed Pervez, James Gair Ford, Richard Anthony Storey, Paul Alfred Dickinson
  • NOVEL HYDROGEN SULFATE SALT
    Publication number: 20140221443
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Application
    Filed: January 10, 2014
    Publication date: August 7, 2014
    Applicants: Astrazeneca AB, Array BioPharma Inc.
    Inventors: John DeMattei, Tsung-Hsun Chuang, Gorkhn Sharma-Singh, Paul Alfred Dickinson, Mohammed Pervez, Richard Anthony Storey, Christopher John Squire, James Gair Ford, Ronald John Roberts
  • NOVEL HYDROGEN SULFATE SALT
    Publication number: 20120253049
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Application
    Filed: May 3, 2012
    Publication date: October 4, 2012
    Inventors: John DeMattei, Tsung-Hsun Chuang, Christopher John Squire, Ronald John Roberts, Gorkhn Sharma-Singh, Mohammed Pervez, James Gair Ford, Richard Anthony Storey, Paul Alfred Dickinson
  • NOVEL HYDROGEN SULFATE SALT
    Publication number: 20100016393
    Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.
    Type: Application
    Filed: December 12, 2006
    Publication date: January 21, 2010
    Inventors: John DeMattei, Tsung-Hsun Chuang, Christopher John Squire, Ronald John Roberts, Gorkhn Sharma-Singh, Mohammed Pervez, James Gair Ford, Richard Anthony Storey, Paul Alfred Dickinson
  • TOSYLATE SALT OF 6- (4-BR0M0-2-CHL0R0PHENYLAMIN0) -7-FLUORO-N- (2-HYDROXYETHOXY) -3-METHYL-3H-BENZIMI DAZOLE- 5 - CARBOXAMIDE , MEK INHIBITOR USEFUL IN THE TREATMENT OF CANCER
    Publication number: 20090030058
    Abstract: The present invention relates to a tosylate salt of Compound 1 and polymorphs thereof, in particular crystalline and amorphous forms of Compound 1 tosylate salt, and methods of preparation thereof. Pharmaceutical compositions containing these salts as active ingredient, their use in the manufacture of medicaments for use in the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body, and their use in methods for the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body are also described.
    Type: Application
    Filed: December 18, 2006
    Publication date: January 29, 2009
    Inventors: Mohammed Pervez, Ronald John Roberts, Christopher John Squire, Richard Anthony Storey
  • Amorphous compound
    Patent number: 6627760
    Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: September 30, 2003
    Assignee: AstraZeneca AB
    Inventor: Ronald John Roberts
  • AMORPHOUS COMPOUND
    Publication number: 20030171301
    Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.
    Type: Application
    Filed: June 25, 2001
    Publication date: September 11, 2003
    Inventor: Ronald John Roberts
  • Amorphous compound
    Patent number: 6462174
    Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: October 8, 2002
    Assignee: AstraZeneca AB
    Inventor: Ronald John Roberts
  • Lisinopril compositions having large-particle DCPD
    Patent number: 6462022
    Abstract: The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m2g−1. The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: October 8, 2002
    Assignee: AstraZeneca AB
    Inventors: Ronald John Roberts, David Brandon Bowen
  • Amorphous compound
    Patent number: 6458769
    Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: October 1, 2002
    Assignee: AstraZeneca AB
    Inventors: Ronald John Roberts, John Brown